IFAH-Europe Welcomes New ESVAC Strategy 2016-2020

Written by IFAH-Europe on 8 April 2016 in Press Release
Press Release

IFAH-Europe Welcomes New ESVAC Strategy 2016-2020, should give fuller picture of antibiotic consumption in animals.

Brussels, 8 April 2016 – The European Medicines Agency has launched its new European Surveillance Veterinary Antimicrobial Consumption project’s (ESVAC) vision and strategy document 2016-2020. IFAH-Europe is pleased to note that ESVAC will be looking at the use of antibiotics in different animal species for the first time, which should enable policy-makers to develop better targeted and refined policies to fight AMR (antimicrobial resistance) effectively.

Europe’s animal health industry has always been a strong supporter of the ESVAC project, and we welcome the European Medicines Agency’s consultation process in which we are happy to participate. The ESVAC project has undergone a process of continual development and improvement since its inception in 2009. Increasing the sophistication of the data collection to provide a reasonable estimate of consumption by species is a next important step in this process.

We are strong advocates for the responsible use of antibiotics in farm animals which needs to go hand in hand with excellent hygiene, biosecurity and good husbandry on farms. Despite all these measures however, infectious diseases in animals still naturally occur, and in the interest of the health and well-being of animals, effective antibiotics are vital to treat animals with a bacterial infection. The goal of responsible use ultimately is to come to a use of antibiotics ‘as little as possible, as much as necessary’.

IFAH-Europe strongly believes that the objective of reducing AMR development needs to involve awareness raising of correct use and the elimination of unnecessary and incorrect use of antibiotics, in both animals and people.

AMR is a major challenge for society, and the animal health industry has an important role to play in focussing on both the correct use, i.e. the prescribed course must be completed, and correct dosages which must be given and followed, after diagnosis and under prescription by a veterinarian.

 

About the author

IFAH-Europe is the representative body of manufacturers of veterinary medicines, vaccines and other animal health products in Europe. It represents innovators and generics alike, as well as large, medium-sized and small companies. IFAH-Europe promotes a single market in veterinary medicines across the EU ensuring the availability of medicines to protect the health and welfare of animals.
Follow IFAH-Europe on @IFAHEurope
Like us on Facebook: www.facebook.com/WeCare.petsEurope
 
For further information, please contact
Kim Hardie - Communications Director
Tel: +32 2 543 75 75
E-mail k.hardie@ifahsec.org

Share this page

Tags

Categories

Partner content

This content is published by the Parliament Magazine on behalf of our partners.

Related Partner Content

PM+: EU animal testing standards lead the world
13 May 2015

Responsibility and welfare on animal testing go hand in hand, argues Françoise Grossetête.

PM+: GMO authorisation needs legal certainty
26 October 2015

Ahead of the European Parliament’s vote on the use of GMOs, Nathalie Moll calls for a shift to a more coherent and science-based approach to EU policymaking.

GMOs: Time to stand up for EU law and innovation
2 June 2016

MEPs have the chance to support innovation and evidence-based authorisation procedures when they meet next week in Strasbourg, says Pedro Narro Sanchez.